Wockhardt Limited
WOCKPHARMA
Rang in Aktien
#4504
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Aktienkurs
$21.02
Marktkapitalisierung
$3.42B
Veränderung (1 Tag)
-2.48%
Veränderung (1 Jahr)
37.78%
Land
IN
Handel Wockhardt Limited (WOCKPHARMA)
Kategorie
Healthcare
Operative Marge für Wockhardt Limited (WOCKPHARMA)
Operative Marge zum October 2026 TTM: 13.78%
Laut den neuesten Finanzberichten und dem Aktienkurs von Wockhardt Limited beträgt die aktuelle operative Marge (TTM) 13.78%. Am Ende des Jahres 2024 lag die operative Marge bei 29.55%.
Historie der operativen Marge von Wockhardt Limited von 2004 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 13.78% | -60.31% |
| 2025 | 34.72% | 17.50% |
| 2024 | 29.55% | -555.32% |
| 2023 | -6.49% | -769.07% |
| 2022 | 0.97% | -108.37% |
| 2021 | -11.59% | 252.28% |
| 2020 | -3.29% | 338.67% |
| 2019 | -0.75% | -85.60% |
| 2018 | -5.21% | 70.26% |
| 2017 | -3.06% | -136.34% |
| 2016 | 8.42% | -44.64% |
| 2015 | 15.21% | -12.54% |
| 2014 | 17.39% | -50.41% |
| 2013 | 35.07% | 21.64% |
| 2012 | 28.83% | 33.84% |
| 2011 | 21.54% | 37.64% |
| 2010 | 15.65% | -23.62% |
| 2008 | 20.49% | -4.87% |
| 2007 | 21.54% | -3,091.67% |
| 2006 | -0.72% | -136.36% |
| 2005 | 1.98% | -89.48% |
| 2004 | 18.82% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 62.34% | -95.48% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.94% |
US
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.